Journal of Nanobiotechnology,
Journal Year:
2024,
Volume and Issue:
22(1)
Published: Dec. 18, 2024
Rheumatoid
arthritis
(RA)
is
an
autoimmune
disorder
characterized
by
painful
swelling
and
inflammation,
arising
from
the
immune
system
attacking
on
healthy
cells.
However,
arthritic
sites
often
experience
increased
lymph
flow,
hastening
drug
clearance
potentially
reducing
treatment
effectiveness.
To
address
this
challenge,
in
situ
size
amplification
has
been
proposed
to
reduce
lymphatic
thereby
enhance
therapy.
This
developed
based
a
conjugate
of
dexamethasone
(Dex)
polysialic
acid
(PSA),
linked
via
acid-sensitive
linker,
supplemented
with
bis-5-hydroxytryptamine
(Bis-5HT)
PSA
backbone.
Under
physiological
conditions,
autonomously
assembles
into
stable
nanoparticles
(PD5NPs),
facilitating
prolonged
circulation
targeted
delivery
inflamed
joints.
Upon
arrival
at
joints,
Bis-5HT
reacts
elevated
myeloperoxidase
(MPO)
levels
oxidative
stress,
prompting
particle
aggregation
in-situ
amplification.
nanocarrier
effectively
reduces
serves
as
reservoirs
for
sustained
Dex
release
acidic
pH
environments
within
sites,
thus
continuously
alleviating
RA
symptoms.
Moreover,
investigation
underlying
mechanism
elucidates
how
influences
transportation
PD5NPs
joints
vessels.
Our
study
offers
valuable
insights
optimizing
nanomedicine
performance
vivo
augmenting
therapeutic
efficacy.
Advanced Science,
Journal Year:
2024,
Volume and Issue:
11(28)
Published: May 17, 2024
Abstract
Organic
near‐infrared
(NIR)
room
temperature
phosphorescence
(RTP)
materials
become
a
hot
topic
in
bioimaging
and
biosensing
for
the
large
penetration
depth
high
signal‐to‐background
ratio
(SBR).
However,
it
is
challenging
to
achieve
persistent
NIR
severe
nonradiative
transitions
by
energy‐gap
law.
Herein,
universal
system
with
RTP
built
visible
(host)
(guest)
materials,
which
can
efficiently
suppress
rigid
environment
of
crystalline
host
good
matching,
further
promote
emission
additional
resonance
energy
transfer
(≈100%)
between
them.
The
ten‐folds
enhancement
lifetimes,
compared
those
guest
luminogens,
be
achieved
modulation
aggregated
structures
host–guest
systems.
This
work
provides
convenient
way
largely
prolong
lifetimes
various
promoting
their
application
afterglow
imaging
deeper
higher
SBRs.
American Journal of Psychiatry,
Journal Year:
2024,
Volume and Issue:
181(5), P. 362 - 371
Published: May 1, 2024
Substance
use
disorders
(SUD)
present
a
worldwide
challenge
with
few
effective
therapies
except
for
the
relative
efficacy
of
opioid
pharmacotherapies,
despite
limited
treatment
access.
However,
proliferation
illicit
fentanyl
initiated
dramatic
and
cascading
epidemic
lethal
overdoses.
This
rise
in
overdoses
regenerated
an
interest
vaccine
immunotherapy,
which,
optimistic
start
animal
models
over
past
50
years,
yielded
disappointing
results
human
clinical
trials
vaccines
against
nicotine,
stimulants
(cocaine
methamphetamine),
opioids.
After
brief
review
selected
preclinical
studies,
"lessons
learned"
from
previous
are
summarized,
then
newest
its
analogs
is
explored.
Animal
studies
have
made
significant
advances
technology
SUD
resulting
anti-fentanyl
show
remarkable
promise
ending
this
deaths.
ACS Omega,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 28, 2025
Despite
the
outstanding
performance
of
monoclonal
antibodies
(mAbs)
in
clinic,
their
full
potential
has
been
hindered
due
to
inability
cross
cell
membranes
and
therefore
reach
intracellular
targets.
The
use
nanotechnology
deliver
mAbs
domains
highlighted
as
a
strategy
with
high
potential.
Working
toward
this
goal,
we
have
recently
developed
validated
palmitoyl
hyaluronate
(HAC16)-based
nanoassemblies
(HANAs),
novel
technology
for
delivery
Kirsten
Rat
Sarcoma
Virus
(KRAS)-mutated
tumors,
one
most
prevalent
challenging
oncoprotein.
success,
pharmacokinetics
biodistribution
these
vehicles
are
still
unknown
chemical
complexity,
challenge
common
large
proportion
drug
nanomedicines.
To
support
further
development
clinical
translation,
present
an
efficient
radiolabeling
approach
positron
emitter
zirconium-89
(89Zr)
vivo
evaluation
HANAs
by
whole-body
PET
imaging.
Additionally,
assessed
impact
PEGylation
size
modulation
on
profile
using
89Zr-radiolabeled
PEGylated
non-PEGylated
HANAs.
Our
imaging
results
demonstrated
that
significantly
modify
89Zr-mAb.
Furthermore,
established
can
be
conveniently
modulated
introducing
PEG
polymers
surface,
facilitating
customization
cancer
applications.
This
versatile
provides
facile
complex
nanoformulations
loaded
mAbs,
quantitative
manner
sensitivity.
Journal of Liposome Research,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 6
Published: March 8, 2025
Lymphography
is
a
useful
technique
in
the
diagnosis
of
lymphatic
diseases.
Conventional
lymph
node
imaging
methods,
such
as
subcutaneous
and
footpad
injections,
are
invasive
unable
to
visualize
mesenteric
nodes.
Liposomes
have
potential
increase
oral
bioavailability
poorly
bioavailable
hydrophilic
drugs
promote
their
transport
intestinal
lymph.
In
this
study,
iohexol
liposome
was
prepared
using
cholesterol,
soybean
lecithin,
by
reverse-phase
evaporation
method.
It
had
an
encapsulation
efficiency
70.26%,
average
particle
size
diameter
185.7
nm,
polydispersity
index
0.275,
zeta
−7.697
mV.
The
liposomes
were
stable
for
five
days
at
4
°C
under
static
conditions.
content
nodes
mice
after
initially
increased
then
gradually
decreased
over
time,
with
absorption
peak
occurring
around
50–70
minutes
5.09
mg/g.
After
administration
liposomes,
mild
enhancement
(12.46–12.92
HU)
observed
dogs
through
CT
scanning
certain
period.
These
results
indicate
that
when
administered
orally,
can
effectively
achieve
Overall,
we
provide
novel
noninvasive
modality
based
on
evaluating
via
lymphography.
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(4), P. 397 - 397
Published: March 21, 2025
Peptide
and
protein
(PP)
therapeutics
are
highly
specific
potent
biomolecules
that
treat
chronic
complex
diseases.
However,
their
oral
delivery
is
significantly
hindered
by
enzymatic
degradation,
instability,
poor
permeability
through
the
gastrointestinal
(GI)
epithelium,
resulting
in
low
bioavailability.
Various
strategies
have
emerged
as
transformative
solutions
to
address
existing
challenges,
offering
enhanced
protection,
stabilization,
absorption
of
PPs.
These
primarily
focus
on
two
major
challenges:
protecting
PP
against
harsh
conditions
enhancing
permeation
across
intestinal
membrane.
Innovative
approaches
such
pH
modulation
incorporation
enzyme
inhibitors
usually
used
mitigate
proteolytic
degradation
during
transit
GI
tract.
In
a
similar
vein,
enhancers
prodrug
facilitate
epithelial
transport,
while
targeted
systems
areas
tract
enhance
absorption.
Likewise,
mucus-penetrating
mucoadhesive
retention
interaction
with
cells,
effectively
overcoming
barriers
like
mucus
layer
tight
junctions.
Furthermore,
structural
modifications
lipidation,
peptide
cyclization,
polyethylene
glycosylation
promising
alternatives
render
stability,
prolong
circulation
time,
membrane
permeability.
particular,
functional
biomaterials,
active
targeting,
lymphatic
transport
provided
new
platforms
for
delivery.
Advancing
materials
science,
nanotechnology,
disruption
medical
devices
holds
frontiers
overcome
barriers.
Despite
substantial
advancements,
limited
success
clinical
translation
underscores
urgency
innovative
strategies.
This
review
presents
PPs
platform,
highlighting
key
transform
therapeutic
landscapes.
